Table 1.
DAS profile of the ipsilateral hind limb of mice after each repeated IM injection of the BoNT/A formulations (12 U/kg per dose) to the right gastrocnemius.
| Dosing Cycle | Parameter | Coretox® | Xeomin® | Botox® |
|---|---|---|---|---|
| First IM Injection | DASmax | 3.1 ± 0.4 a | 2.8 ± 0.5 a | 3.0 ± 0.0 a |
| (Day 0) | Duration (days) | 42.0 ± 8.4 a | 35.0 ± 8.4 a | 45.4 ± 11.0 a |
| DASAUC (DAS·day) | 59.4 ± 11.5 b | 40.4 ± 16.4 a | 55.1 ± 13.8 a,b | |
| Second IM Injection | DASmax | 3.0 ± 0.0 b | 2.5 ± 0.5 a | 2.9 ± 0.4 a,b |
| (Day 84) | Duration (days) | 52.5 ± 11.2 b | 33.1 ± 14.3 a | 41.8 ± 11.0 a,b |
| DASAUC (DAS·day) | 75.6 ± 27.6 b | 34.7 ± 17.2 a | 51.0 ± 17.1 a,b | |
| Third IM Injection | DASmax | 3.0 ± 0.0 b | 2.0 ± 0.5 a | 2.6 ± 0.5 b |
| (Day 168) | Duration (days) | 68.3 ± 13.4 b | 32.4 ± 11.8 a | 44.6 ± 10.5 a |
| DASAUC (DAS·day) | 103.4 ± 27.4 b | 29.9 ± 16.0 a | 57.1 ± 23.2 a |
DASmax, maximum paresis; duration, duration of action; DASAUC, cumulative DAS per injection cycle; Data represent mean ± standard deviation. One-way ANOVA with Tukey’s HSD test was used (mean values with different superscript letter are significantly different at α = 0.05).